Home

arrow iconNewsarrow iconarrow icon

INVO Fertility, Inc. Announces WFI Clinic Joined the Progyny Network to Expand Patient Access

INVO Fertility, Inc. Announces WFI Clinic Joined the Progyny Network to Expand Patient Access

INVO Fertility, Inc has confirmed that its Wisconsin Fertility Institute-WFI clinic joined the Progyny network, making advanced reproductive care more widely available and accessible for more patients seeking fertility treatment.

By FertilityIn

10 Mar 2026

3 min read

Invo Logo

Invo Logo

INVO Fertility, Inc., a fertility company that seeks to make advanced reproductive care more available by opening, buying, and running fertility clinics and related businesses and technologies, says that its Wisconsin Fertility Institute-WFI clinic joined the Progyny network.


Progyny offers fertility and family-building advantages to about 7.2 million people through more than 600 employers and plan sponsors across the country. WFI's potential market in Wisconsin and the neighbouring areas is bigger now that it is part of the Progyny network. This arrangement makes it much easier for the clinic to visit patients whose companies cover them.


Patients who meet the requirements can now get all of WFI's reproductive services, including diagnostic testing, in vitro fertilisation (IVF), fertility preservation, and other advanced treatment options, all through their network. Progyny's scientifically integrated benefit design makes it easier for patients to keep track of their money and paperwork. The program decreases barriers to care and helps people use therapy more effectively and receive better results. Progyny is a big part of the fertility business because it helps patients with the two biggest problems they have: getting care and paying for it.


As the WFI clinic joined the Progyny network, it improved its mix of third-party payers from a business point of view and lets it help more people who require care. As more and more companies offer reproductive benefits, it is becoming more and more necessary to work with the best fertility benefits administrators to promote organic growth.


Employer-sponsored fertility benefits are one of the fastest-growing parts of healthcare benefits. Companies want to hire and keep the best workers, so they offer these benefits. INVO Reproductive believes that making its services easier to find on well-known national benefit platforms will help it stay competitive and assist its increasing network of reproductive centres to grow even further. The company sees the move as a big step forward and an important part of its overall plan to grow its clinic platform, build stronger relationships with payers, and improve its long-term financial performance.


According to COO of INVO Fertility, April McGhee, “We are excited to join the Progyny network, a leader in fertility benefits known for its commitment to transparency, exceptional client and member satisfaction, and superior clinical outcomes." This partnership expands access to high-quality fertility treatment for more patients while reinforcing our focus on delivering exceptional results and a seamless, supportive care experience. We look forward to helping Progyny members build their families with confidence.”


Steve Shum, CEO of INVO Fertility, says that “This relationship expands our addressable patient base and strengthens our access to employer-sponsored demand." “As we continue to grow through strategic clinic development and acquisitions, establishing relationships with leading benefits providers like Progyny represents a further enhancement to our growth objectives, operating leverage, and ability to drive long-term value creation for our shareholders.”

9 views

Share

FertilityIn

Send Enquiry for this Story

Related Articles

Can AI Pick IVF Embryos Better Than Humans?

Can AI Pick IVF Embryos Better Than Humans?

A groundbreaking Nature Medicine study compares AI deep learning against expert embryologists in selecting embryos. While pregnancy rates remain comparable, the study uncovers a massive advantage in efficiency that could revolutionize IVF labs worldwide. Discover how AI-driven embryo selection accuracy is reshaping the future of fertility treatment.

ART

1 min read

FertilAI Secures World's First CE Mark for Predictive AI in Fertility Treatment

FertilAI Secures World's First CE Mark for Predictive AI in Fertility Treatment

FertilAI has received EU MDR clearance for tools advancing Predictive AI in Fertility through its Fertilane platform. StimAI and OvuPredict help clinicians optimise IVF timing, predict ovulation and improve scheduling efficiency. The technology supports scalable fertility care, reduced monitoring needs and better patient treatment experiences globally.

ART

1 min read

Ferring Pharma and Gallup announce Global Fertility Monitor

Ferring Pharma and Gallup announce Global Fertility Monitor

The Ferring Global Fertility Monitor has been launched by Ferring Pharmaceuticals and Gallup to examine fertility trends in 70 countries. Through large-scale surveys, the project will explore economic, social, and cultural influences on parenthood decisions. Insights are expected to guide policy, healthcare planning, and future demographic strategies.

ART

1 min read

Maven Clinic Expands Fertility and Family Building Program with New Diagnostic Tools and Wearable Data Integration

Maven Clinic Expands Fertility and Family Building Program with New Diagnostic Tools and Wearable Data Integration

Maven Clinic has expanded its Fertility and Family Building program with earlier diagnostics, wearable integration, and AI-powered personalised care. The enhanced platform supports faster diagnosis, improved treatment decisions, and condition-specific pathways for PCOS, endometriosis, and oncofertility. The rollout continues through 2026 with added innovations and partnerships.

ART

1 min read

Debate Goes on the Legalization of Egg Donation in Germany

Debate Goes on the Legalization of Egg Donation in Germany

Germany is debating the legalization of egg donation in Germany, challenging decades-old restrictions under the Embryo Protection Act. Experts argue reform is overdue to align with modern reproductive science, reduce fertility tourism, and improve patient care, while policymakers work to balance ethical concerns with growing demand for advanced fertility treatments.

ART

1 min read

New Research Links Forever Chemicals to Reduced ART Outcomes

New Research Links Forever Chemicals to Reduced ART Outcomes

A new review highlights the link from Forever Chemicals to reduced ART outcomes, showing how PFAS exposure impacts fertility, pregnancy, and reproductive health. The findings raise urgent concerns for IVF patients and call for stronger regulation, deeper research, and systemic action to address environmental risks in reproductive medicine.

ART

1 min read

Addressing the Infertility Crisis: New Directions in the 2027 Title X NOFO

Addressing the Infertility Crisis: New Directions in the 2027 Title X NOFO

The 2027 Title X NOFO introduces a major policy shift toward addressing infertility crisis in the U.S. It mandates basic infertility services, expands male reproductive health focus, and promotes education on body literacy and lifestyle factors, aiming to support family formation alongside traditional contraceptive services.

ART

1 min read

Landing Page Image

Subscribe to our Newsletter

Stay updated with the latest news, expert insights, and exclusive offers delivered straight to your inbox. Join our community today!

Email Address